From Yahoo Finance: 2025-06-03 10:35:00

Hims & Hers is acquiring European telehealth platform Zava, expanding its presence in the U.K., Germany, France, and Ireland. The deal brings 1.3 million active users to the company, positioning it to introduce digital healthcare in major European markets, focusing on weight-loss drugs.

The terms of the all-cash deal were not disclosed, but Hims & Hers stock surged 17% after the announcement. The company’s stock has risen 165% year to date, driven by its direct-to-consumer offerings such as hair loss, sexual health, and anxiety treatments.

Hims & Hers CEO Andrew Dudum sees a significant opportunity in obesity, with Zava already offering weight-loss treatments. The company’s compounded GLP-1 medications have been a fast-growing offering in the U.S., and the acquisition of Zava could pave the way for similar custom formulations in Europe.

The acquisition of Zava could allow Hims & Hers to offer compounded medications in the U.K., where regulations permit it under certain conditions. Lower pharmaceutical prices and public health system constraints in Europe may drive adoption of the company’s offerings, potentially accelerating its international growth.

With the Zava deal, Hims & Hers aims to establish a branded footprint in key European markets, leveraging Zava’s infrastructure. The company’s previous acquisition in London in 2021 laid the groundwork for international expansion, and the Zava deal further solidifies its presence in Europe.

Zava CEO David Meinertz will continue to lead the international business post-acquisition, with the Zava brand expected to transition to Hims & Hers over time. Meinertz believes the deal could alleviate pressure on Europe’s healthcare systems by offering more affordable medications and meeting growing demand for telehealth services.



Read more at Yahoo Finance: Hims & Hers makes a big Europe push with an acquisition. Knockoff weight loss drugs could be next